Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 1,851–1,875 of 2,047 studies published 2026 (page 75 of 82) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Pharmacotherapy for Alzheimer’s Disease and Dementias in Long-Term Care: A Real-World EHR Study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-01-19

More than one-quarter of residents with ADRD remain untreated with guideline-recommended pharmacotherapy, and treatment varied significantly by non-clinical predictors. 5 key findings →

Participants: 359,801 Evidence: low

Real-terms UK government spending on health-related long-term care grew by £6.4 billion (22.9%) between 2013 and 2022, from £27.9 to £34.3 billion. 3 key findings →

Evidence: low

Preventive and Need-Driven Use of Dental Services among Community-Dwelling Older People with Long-Term Care Needs

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-01-30

Oral health is a key component of quality of life among older adults, yet maintaining preventive dental care becomes increasingly difficult for those with long-term care (LTC) needs. 4 key findings →

Participants: 1,055 Evidence: low

Passive sleep monitoring identified physiologically interpretable sleep markers associated with next-day agitation occurrence, supporting prospective evaluation of under-mattress sensing as a source of short-term risk information for dementia care. 4 key findings →

Participants: 55 Evidence: moderate

Contexts and mechanisms associated with attendees’ and caregivers’ social determinants of health, and system-level contexts and mechanisms that influence ADPs are important knowledge gaps to be addressed by studies and to be incorporated in our program theory in the future. 3 key findings →

Participants: 17 Evidence: low

MinderCare: protocol for a mixed-methods evaluation of a digitally enabled dementia care service

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-06-22

Strengths and limitations of this study This study evaluates a digitally enabled remote monitoring model for people living with dementia that integrates passive in-home sensors and algorithm-derived digital biomarkers to detect clinically relevant changes such as infection risk, behavioural disturbance and physiological deterioration. 5 key findings →

Participants: 100 Evidence: high

Patient-Reported Shared Decision-Making and Documented Advance Care Planning Among Adults With Alzheimer’s Disease and Related Dementias

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-19

Among adults with ADRD, high SDM was associated with greater ACP prevalence in unadjusted analyses, although the fully adjusted association was not statistically significant. 5 key findings →

Participants: 3,635 Evidence: moderate

Two analytical themes were identified: (1) challenges in preserving the person's voice throughout the dementia trajectory, reflecting a shift toward caregiver-mediated decision-making, assumptions about capacity, and delayed ACP initiation; and (2) challenges in maintaining continuity of expressed values and preferences over time, reflecting uncertainty about future care needs and the limitations of one-time ACP conversations. 5 key findings →

Evidence: low

Person-Centred Care: Impact on the Effectiveness of Palliative Care in Patients with Alzheimer’s Disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-29

The increasing prevalence of Alzheimer’s disease (AD) underscores the need for care models that preserve identity, autonomy, and comfort throughout disease progression. 2 key findings →

Evidence: low

AI on Alzheimer Disease: Large-Scale Reproduction Shows the Field’s Hypotheses Cannot Be Distinguished on Common Data

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-27

After more than three decades of intensive research, Alzheimer disease care remains largely palliative, and the field has drawn sustained criticism, both for that reason and for pursuing some directions of inquiry over others. 5 key findings →

Evidence: low

Seven routine blood markers predict five-year mortality in older Indians: a risk score from the LASI-DAD cohort

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-09

Among 2144 participants (540 deaths over a median 4.4 years of survivor follow-up; 25% mortality), the seven-marker score plus age and sex achieved an apparent C of 0.74 (optimism-corrected 0.74), versus 0.68 for age and sex alone (Δ ≈ 0.06); the blood panel alone reached C 0.72. 2 key findings →

Design: longitudinal study Participants: 2,144 Evidence: moderate

Turkish Adaptation of the Supportive and Palliative Care Indicators Tool (SPICT): A Validity and Reliability Study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-06

The SPICT-TR is a culturally adapted, valid, and reliable assessment tool for identifying patients with palliative care needs within the Turkish healthcare system. 4 key findings →

Participants: 356 Evidence: low

Understanding end-of-life multimorbidity: An analysis of multiple causes of death in Denmark

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-07-07

We examined how often each diagnosed disease appeared on the certificate, its location and selection as the UCD, factors associated with its appearance (logistic regression), disease-specific mortality (multiple decrement life tables), and disease associations (Cause of Death Association Indicator, CDAI). 3 key findings →

Evidence: moderate

Data collection started on June 3, 2026, and is planned to close on June 30, 2026. 2 key findings →

Design: cross-sectional Evidence: low

Polypharmacy and PIMs are highly prevalent in end-of-life elderly cancer patients. 3 key findings →

Design: cross-sectional Participants: 183 Evidence: low

Prevalence of dementia and mild cognitive impairment in Morocco: A population-based study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-22

This nationwide study provides epidemiological data on dementia and MCI among adults aged ≥ 60 years across all 12 administrative regions of Morocco. 1 key finding →

Design: cross-sectional Participants: 1,662 Evidence: low

This study reports the prevalence of CF among elderly hypertensive residents of a community in Inner Mongolia. 5 key findings →

Design: cross-sectional Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed